Overall Status

Completed (1)

Recruiting (1)

Unknown status (1)

Sign in for free

Phase

early phase 1 (1)

phase 1/phase 2 (1)

phase 2 (1)

Sponsor

Memorial Sloan Kettering Cancer Center (1)

Nantes University Hospital (1)

Shenzhen University General Hospital (1)

Collaborator

Actinium Pharmaceuticals (1)

Intervention

131-i apamistamab (1)

car t-cell (1)

dual target car-t cell therapy (1)

epratuzumab (1)

Study Documents

Intervention Type

biological (2)

drug (2)

Funder Type

Other (3)

Study Type

Interventional (3)

b all

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

B-ALL, DLBCL, B ALL Trial in New York (131-I Apamistamab, CAR T-cell)

Recruiting

B-ALL
+10 more

131-I Apamistamab
CAR T-cell

New York, New York

Memorial Sloan Kettering Cancer Center

Mar 7, 2022

Dual-target CAR-T Cells, B ALL, Relapse Trial in Shenzhen (Dual target CAR-T cell therapy)

Unknown status

Dual-target CAR-T Cells
+3 more

Dual target CAR-T cell therapy

Shenzhen, Guangdong, China

Shenzhen University General hospital

Jan 23, 2021

B ALL, CD22+ Expression, Refractory B-ALL Trial in France (Epratuzumab)

Completed

B ALL
+2 more

Epratuzumab

Angers, France
+10 more

Feb 26, 2018